{"id":"albumin-bound-paclitaxel-plus-s-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albumin-bound paclitaxel (nab-paclitaxel) is a taxane that stabilizes microtubules and prevents their disassembly, leading to mitotic arrest and apoptosis in cancer cells. S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and incorporates into DNA/RNA, disrupting nucleotide synthesis. The combination leverages complementary mechanisms of action to enhance antitumor activity.","oneSentence":"Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:32.482Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (phase 3 investigation)"},{"name":"Potentially other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06519591","phase":"PHASE2","title":"Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-02-25","conditions":"Gastric Cancer Stage IV, Peritoneal Metastases","enrollment":40},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07384234","phase":"PHASE2","title":"SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-31","conditions":"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","enrollment":60},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT07182565","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy","enrollment":84},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT07085234","phase":"PHASE2","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-07-30","conditions":"Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy","enrollment":30},{"nctId":"NCT06966440","phase":"NA","title":"Adjuvant Pancreatic Therapy Guided by MRD","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Pancreatic Adenocarcinoma Resectable","enrollment":856},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT07018063","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"zhoujing","startDate":"2025-10-01","conditions":"Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced","enrollment":35},{"nctId":"NCT06921252","phase":"","title":"Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?","status":"COMPLETED","sponsor":"Kochi University","startDate":"2010-01-01","conditions":"Pancreatic Cancer Metastatic","enrollment":276},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT04195828","phase":"PHASE2","title":"Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2020-06-18","conditions":"Advanced Gastric Cancer","enrollment":106},{"nctId":"NCT06901622","phase":"PHASE2","title":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-11-08","conditions":"Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT06789679","phase":"PHASE2","title":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-25","conditions":"Pancreatic Adenocarcinoma","enrollment":128},{"nctId":"NCT05218889","phase":"PHASE1, PHASE2","title":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2021-08-04","conditions":"Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer","enrollment":90},{"nctId":"NCT06662877","phase":"PHASE2, PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":"Biliary Tract Cancer, Second Line Treatment, Chemotherapy","enrollment":206},{"nctId":"NCT06487715","phase":"PHASE2","title":"Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis","status":"ENROLLING_BY_INVITATION","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-03-01","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":42},{"nctId":"NCT06454435","phase":"PHASE2","title":"Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":158},{"nctId":"NCT05540145","phase":"","title":"Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-05-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT05101616","phase":"PHASE1, PHASE2","title":"A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer","status":"SUSPENDED","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2022-07-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT04694183","phase":"PHASE2","title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Quan Wang","startDate":"2020-08-17","conditions":"Stomach Neoplasms","enrollment":37},{"nctId":"NCT06229496","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":70},{"nctId":"NCT06169410","phase":"PHASE4","title":"Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Advanced Gastric Cancer","enrollment":140},{"nctId":"NCT06213519","phase":"PHASE2","title":"HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-02-20","conditions":"Peritoneal Metastases, Gastric Cancer","enrollment":69},{"nctId":"NCT02535988","phase":"PHASE2","title":"Abscopal Effect for Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2015-09","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin","enrollment":""},{"nctId":"NCT06046963","phase":"PHASE2","title":"Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-03-01","conditions":"Gastric Cancer, Peritoneal Metastases, Ascites, Malignant","enrollment":35},{"nctId":"NCT03777462","phase":"PHASE2","title":"Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":150},{"nctId":"NCT02995850","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-02-22","conditions":"Gastric Cancer With Peritoneal Metastasis (PCI<12)","enrollment":25},{"nctId":"NCT04267549","phase":"PHASE2","title":"Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-05-01","conditions":"Gastric Cancer Stage IV","enrollment":47},{"nctId":"NCT05853172","phase":"PHASE2","title":"Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-03-21","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT05687357","phase":"PHASE2","title":"Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-03-15","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":140},{"nctId":"NCT05052931","phase":"PHASE2","title":"Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Jianjun Yang","startDate":"2021-10-01","conditions":"Gastric Cancer","enrollment":10},{"nctId":"NCT04047953","phase":"NA","title":"Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-09-10","conditions":"Gastric Adenocarcinoma","enrollment":95},{"nctId":"NCT05627414","phase":"PHASE2","title":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT05524974","phase":"PHASE2","title":"Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2022-09-01","conditions":"Locally Advanced Gastric Cancer","enrollment":203},{"nctId":"NCT05497739","phase":"PHASE2","title":"Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-06-28","conditions":"Gastric Cancer","enrollment":68},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05441254","phase":"PHASE2","title":"Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study","status":"UNKNOWN","sponsor":"Zhongshan Hospital Xiamen University","startDate":"2022-07","conditions":"Stage IV Gastric Cancer With Metastasis","enrollment":33},{"nctId":"NCT05410847","phase":"PHASE2","title":"Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2022-06-30","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT04675866","phase":"NA","title":"Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-08-17","conditions":"Advanced Gastric Adenocarcinoma","enrollment":46},{"nctId":"NCT03162510","phase":"PHASE1","title":"Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-06-26","conditions":"Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers","enrollment":18},{"nctId":"NCT02539225","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-05","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":191},{"nctId":"NCT05268692","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","status":"RECRUITING","sponsor":"Kochi University","startDate":"2019-01-01","conditions":"Pancreatic Adenocarcinoma","enrollment":500},{"nctId":"NCT05228743","phase":"NA","title":"Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-09-01","conditions":"Gastric Cancer","enrollment":180},{"nctId":"NCT05204173","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-05-20","conditions":"Gastric Cancer Stage IV, Peritoneal Metastases","enrollment":30},{"nctId":"NCT03801668","phase":"PHASE3","title":"Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2019-03-08","conditions":"Gastric Cancer","enrollment":294},{"nctId":"NCT05138159","phase":"PHASE2","title":"A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-01","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT05111444","phase":"PHASE2","title":"Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-31","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":65},{"nctId":"NCT05095467","phase":"PHASE2","title":"HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Xuefei.Wang","startDate":"2021-10","conditions":"Stomach Neoplasms, Peritoneal Metastases","enrollment":157},{"nctId":"NCT03051373","phase":"PHASE2","title":"Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2017-04-01","conditions":"Carcinoma, Transitional Cell","enrollment":108},{"nctId":"NCT04889768","phase":"NA","title":"HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-07-31","conditions":"Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery","enrollment":46},{"nctId":"NCT04808687","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03","conditions":"Pancreatic Neoplasms","enrollment":72},{"nctId":"NCT04781413","phase":"PHASE1, PHASE2","title":"Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-03-01","conditions":"Stage IIIC Gastric Cancer","enrollment":38},{"nctId":"NCT03415802","phase":"PHASE2","title":"Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Aiping Zhou","startDate":"2015-05-11","conditions":"Advanced Pancreatic Cancer","enrollment":32},{"nctId":"NCT03830606","phase":"PHASE2","title":"The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Aiping Zhou","startDate":"2016-03-23","conditions":"Biliary Tract Cancer","enrollment":54},{"nctId":"NCT03585062","phase":"PHASE2","title":"Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer","status":"TERMINATED","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2017-11-20","conditions":"Pancreatic Cancer, Neoadjuvant Chemotherapy","enrollment":40},{"nctId":"NCT04518800","phase":"NA","title":"PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-08-18","conditions":"PEG-rhG-CSF, Pancreatic Cancer","enrollment":20},{"nctId":"NCT04135781","phase":"PHASE3","title":"Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-03-01","conditions":"Stomach Cancer","enrollment":616},{"nctId":"NCT03850769","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-01","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":60},{"nctId":"NCT03885219","phase":"PHASE2","title":"Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":60},{"nctId":"NCT04258657","phase":"PHASE2","title":"Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2020-03-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT04258644","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2020-03-01","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT03957564","phase":"PHASE2","title":"Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2019-05-28","conditions":"Gastric Cancer, Gastro-oesophageal Junction Cancer","enrollment":40},{"nctId":"NCT04217096","phase":"PHASE4","title":"Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \\ Advanced Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-01-01","conditions":"Advanced Pancreatic Cancer","enrollment":40},{"nctId":"NCT04101929","phase":"PHASE2","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-01","conditions":"Metastatic Pancreatic Cancer","enrollment":126},{"nctId":"NCT03788226","phase":"PHASE3","title":"A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-02-01","conditions":"Gastric Cancer Stage III","enrollment":600},{"nctId":"NCT04121039","phase":"PHASE2","title":"Study of the Apatinib Combine With POF Versus POF in Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-12","conditions":"Gastric Adenocarcinoma, Advanced Cancer","enrollment":116},{"nctId":"NCT00806117","phase":"PHASE3","title":"Comparison of Different Subsequent Treatments After Radical Surgery","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-02-25","conditions":"Cervical Cancer","enrollment":1080},{"nctId":"NCT04027764","phase":"PHASE2","title":"Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Dai, Guanghai","startDate":"2019-05-01","conditions":"Advanced Biliary Tract Cancer","enrollment":30},{"nctId":"NCT03263741","phase":"PHASE2","title":"Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2017-04-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT03779464","phase":"PHASE2","title":"Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-08-01","conditions":"Pancreatic Cancer, Nab-paclitaxel, Gemcitabine","enrollment":132},{"nctId":"NCT03990103","phase":"PHASE2","title":"S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-11-01","conditions":"Metastatic Gastric Adenocarcinoma","enrollment":66},{"nctId":"NCT03977220","phase":"PHASE1","title":"Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-01-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT03815461","phase":"PHASE2","title":"Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-02-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":60},{"nctId":"NCT03718624","phase":"PHASE2","title":"A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2018-10-30","conditions":"Gastric Cancer With Positive Exfoliative Cancer Cells","enrollment":36},{"nctId":"NCT03398291","phase":"PHASE3","title":"Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-07-01","conditions":"Pancreatic Cancer, Liver Metastases, Surgery","enrollment":300},{"nctId":"NCT03636308","phase":"PHASE2","title":"Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-07-17","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT03475615","phase":"PHASE3","title":"A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-03-16","conditions":"Gastric Cancer, Stomach Neoplasms","enrollment":215},{"nctId":"NCT03428425","phase":"PHASE2","title":"A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2018-02","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT01963325","phase":"PHASE2","title":"S-1 in Combination With Abraxane in Treating Cholangiocarcinoma","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2013-08","conditions":"Cholangiocarcinoma","enrollment":50},{"nctId":"NCT02356276","phase":"PHASE3","title":"Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2015-05-11","conditions":"Gastric Cancer","enrollment":584},{"nctId":"NCT03278015","phase":"PHASE2","title":"Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-10-01","conditions":"Cancer of Pancreas","enrollment":90},{"nctId":"NCT03258034","phase":"PHASE2","title":"A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2017-08-24","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT03237507","phase":"","title":"Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Harbin Medical University","startDate":"2017-07-01","conditions":"Stage IV Gastric Cancer With Metastasis","enrollment":110},{"nctId":"NCT02229058","phase":"PHASE2","title":"Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2012-02","conditions":"Gastric Cancer","enrollment":73},{"nctId":"NCT03179579","phase":"PHASE3","title":"Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer","status":"UNKNOWN","sponsor":"Shu-Zhong Cui","startDate":"2017-08-01","conditions":"Gastric Cancer, Peritoneal Carcinomatosis","enrollment":88},{"nctId":"NCT01704690","phase":"PHASE2, PHASE3","title":"Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer","status":"TERMINATED","sponsor":"Peking University","startDate":"2012-08","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT02124317","phase":"PHASE2","title":"Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2014-04","conditions":"Advanced Pancreatic Cancer","enrollment":60},{"nctId":"NCT02960061","phase":"PHASE3","title":"Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-11","conditions":"Survival","enrollment":640}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Albumin-bound Paclitaxel plus S-1","genericName":"Albumin-bound Paclitaxel plus S-1","companyName":"Huazhong University of Science and Technology","companyId":"huazhong-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects. Used for Gastric cancer (phase 3 investigation), Potentially other solid tumors (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}